HIV感染者透析通路建立后结局不劣于未感染者
基于血管质量倡议(VQI)登记2011—2018年25711例上肢动静脉通路建立患者,其中HIV感染424例、艾滋病101例,经4:1倾向评分匹配后比较短期与长期结局。结果显示HIV/艾滋病患者通路再干预、闭塞、死亡风险及1年原发通畅率与未感染者无显著差异,提示应延续现有通路创建与管理策略。
要点
- HIV/艾滋病患者动静脉通路再干预、闭塞及死亡风险与未感染者无显著差异。
- 两组合并需切开引流或移除的通路伤口感染率均较低,组间差异无统计学意义。
- HIV/艾滋病患者更年轻、男性及非白人比例更高,传统终末期肾病危险因素较少。
核心结论
- HIV/艾滋病患者建立动静脉通路后的短期和长期结局与未感染者相似,包括长期生存。
- 现行动静脉通路创建与管理策略在HIV/艾滋病患者中应继续沿用,但尚需进一步研究识别该人群的危险因素。
研究设计与样本
- 回顾性队列研究,查询血管质量倡议(VQI)登记2011—2018年所有动静脉通路建立病例。
- 非HIV感染者与HIV/艾滋病患者按4:1进行倾向评分匹配,随后行多变量分析和Kaplan-Meier分析。
- 平均年龄61.8岁,男性占55.8%。
主要发现
- HIV/艾滋病患者更常年轻、男性、非白人、非肥胖及现吸烟,更常参加医疗补助(Medicaid)并有静脉吸毒史,较少患糖尿病和心脏合并症(P < .05)。
- 各组使用自体或人工血管通路无显著差异。
- 90天内需切开引流或移除的伤口感染率低:非HIV感染组0.6%、HIV感染组1.9%、艾滋病组0%(P = .11)。
- Kaplan-Meier分析示有无HIV/艾滋病的1年免于原发通畅丧失率(43.9% vs 46.3%;P = .6)、1年免于再干预率(61% vs 60.7%;P = .81)及3年生存率(83% vs 83.8%;P = .57)均无显著差异。
- 多变量分析示HIV/艾滋病患者通路再干预(HR 0.97;95%CI 0.76-1.24;P = .81)、闭塞(HR 1.06;95%CI 0.86-1.29;P = .6)和死亡(HR 1.08;95%CI 0.83-1.43;P = .57)风险均未显著升高。
关键数值与推荐
- 1年免于原发通畅丧失率:非HIV感染组43.9% vs HIV/艾滋病组46.3%(P = .6)。
- 1年免于再干预率:非HIV感染组61% vs HIV/艾滋病组60.7%(P = .81)。
- 3年生存率:非HIV感染组83% vs HIV/艾滋病组83.8%(P = .57)。
- 90天伤口感染率:非HIV感染组0.6%、HIV感染组1.9%、艾滋病组0%(P = .11)。
临床怎么用
- 对HIV/艾滋病合并终末期肾病患者,可按现有常规创建和管理动静脉透析通路,无需因HIV状态降低通路创建标准。
- 应结合该人群年轻、吸烟及静脉吸毒史等特点进行个体化随访,但现有证据未显示需改变通路类型选择。
- 临床决策中仍需关注该人群的伤口感染风险,尽管本研究中组间差异无统计学意义。
局限性
- 为回顾性登记研究,可能存在选择偏倚和未测量混杂。
- HIV/艾滋病亚组样本量相对较小(HIV感染424例、艾滋病101例),部分比较可能效能不足。
- 原文未报告匹配后各组的具体样本量及随访时间细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Despite improvements in treating human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), the risk of end-stage renal disease and need for long-term arteriovenous (AV) access for hemodialysis remain high in HIV-infected patients. Associations of HIV/AIDS with AV access creation complications have been conflicting. Our goal was to clarify short- and long-term outcomes of patients with HIV/AIDS undergoing AV access creation. METHODS: The Vascular Quality Initiative registry was queried from 2011 to 2018 for all patients undergoing AV access creation. Documentation of HIV infection status with or without AIDS was recorded. Data were propensity score matched (4:1) between non-HIV-infected patients and HIV/AIDS patients. Subsequent multivariable analysis and Kaplan-Meier analysis were performed for short- and long-term outcomes. RESULTS: There were 25,711 upper extremity AV access creations identified: 25,186 without HIV infection (98%), 424 (1.6%) with HIV infection, and 101 (.4%) with AIDS. Mean age was 61.8 years, and 55.8% were male. Patients with HIV/AIDS were more often younger, male, nonwhite, nonobese, and current smokers; they were more often on Medicaid and more likely to have a history of intravenous drug use, and they were less often diabetic and less likely to have cardiac comorbidities (P < .05 for all). There was no significant difference in autogenous or prosthetic access used in these cohorts. Wound infection requiring incision and drainage or explantation within 90 days was low for all groups (0.6% vs 1.9 vs 0%; P = .11) of non-HIV-infected patients vs HIV-infected patients vs AIDS patients. Kaplan-Meier analysis showed no significant difference in 1-year freedom from primary patency loss (43.9% vs 46.3%; P =.6), 1-year freedom from reintervention (61% vs 60.7%,; P = .81), or 3-year survival (83% vs 83.8%; P = .57) for those with and without HIV/AIDS, respectively. Multivariable analysis demonstrated that patients with HIV/AIDS were not at significantly higher risk for access reintervention (hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.76-1.24; P = .81), occlusion (HR, 1.06; 95% CI, 0.86-1.29; P = .6), or mortality (HR, 1.08; 95% CI, 0.83-1.43; P = .57). CONCLUSIONS: Patients with HIV/AIDS undergoing AV access creation have outcomes similar to those of patients without HIV infection, including long-term survival. Patients with HIV/AIDS had fewer traditional end-stage renal disease risk factors compared with non-HIV-infected patients. Our findings show that the contemporary approach for creation and management of AV access in patients with HIV/AIDS should be continued; however, further research is needed to identify risk factors in this population.
引用
- Dicken QG, Cheng TW, Farber A, et al. Patients with human immunodeficiency virus infection do not have inferior outcomes after dialysis access creation. J Vasc Surg. 2020. PMID: 32276018. doi:10.1016/j.jvs.2020.03.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。